BioPharma Resources

Drug Trial Radar · NCT03006705

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

A Multicenter, Double-blind, Randomized Study in Patients With Gastric Cancer Undergoing Postoperative Adjuvant Chemotherapy

Last checked: Nov 19, 2026Latest source record: May 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

800

Actual

Start

Jan 31, 2017

Primary completion

Aug 17, 2022

Study completion Mar 31, 2023

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Dec 30, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.

Conditions

  • Gastric Cancer

Interventions

  • NivolumabDrug

    Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).

  • Tegafur-gimeracil-oteracil potassiumDrug

    Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off

  • OxaliplatinDrug

    Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.

  • CapecitabineDrug

    Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.

  • PlaceboDrug

    Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relapse-free survival (RFS)Time frame: 5 years

Locations

108 sites in 4 countries. Site status is shown where the registry gives one.

  • Anhui Province Clinical Site

    Anhui Province, China

  • Beijing Clinical Site1

    Beijing, China

  • Beijing Clinical Site2

    Beijing, China

  • Cuangdong Province Clinical Site

    Cuangdong Province, China

  • Guangdong Province Clinical Site1

    Guangdong Province, China

  • Guangdong Province Clinical Site2

    Guangdong Province, China

  • Henan Province Clinical Site1

    Henan Province, China

  • Henan Province Clinical Site2

    Henan Province, China

  • Jiangsu Province Clinical Site1

    Jiangsu Province, China

  • Jiangsu Province Clinical Site3

    Jiangsu Province, China

  • Jiangsu Province Clinical Site4

    Jiangsu Province, China

  • Jiangsu Province Clinical Site5

    Jiangsu Province, China

  • Jiangsu Province Clinical Site6

    Jiangsu Province, China

  • Jiangxi Province Clinical Site2

    Jiangxi Province, China

  • Jilin Province Clinical Site

    Jilin Province, China

  • Liaoning Province Clinical Site

    Liaoning Province, China

  • Shanxi Province Clinical Site

    Shanxi Province, China

  • Tianjin Clinical Site1

    Tianjin, China

  • Tianjin Clinical Site2

    Tianjin, China

  • Zhejiang Province Clinical Site

    Zhejiang Province, China

  • Zhengjiang Province Clinical Site

    Zhengjiang Province, China

  • Chiba Clinical Site

    Chiba, Japan

  • Fukuoka Clinical Site 1

    Fukuoka, Japan

  • Fukuoka Clinical Site 2

    Fukuoka, Japan

  • Gifu Clinical Site

    Gifu, Japan

  • Hiroshima Clinical Site1

    Hiroshima, Japan

  • Hiroshima Clinical Site2

    Hiroshima, Japan

  • Hiroshima Clinical Site3

    Hiroshima, Japan

  • Kochi Clinical Site

    Kochi, Japan

  • Kumamoto Clinical Site

    Kumamoto, Japan

  • Kyoto Clinical Site

    Kyoto, Japan

  • Niigata Clinical Site

    Niigata, Japan

  • Osaka Clinical Site1

    Osaka, Japan

  • Osaka Clinical Site2

    Osaka, Japan

  • Osaka Clinical Site3

    Osaka, Japan

  • Osaka Clinical Site4

    Osaka, Japan

  • Shizuoka Clinical Site

    Shizuoka, Japan

  • Toyama Clinical Site

    Toyama, Japan

  • Wakayama Clinical Site

    Wakayama, Japan

  • Yamagata Clinical Site

    Yamagata, Japan

Showing 40 of 108 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.